Table 1 Stage I and II: sample characteristics by country
Characteristics | Stage I (N = 46) | Stage II (N = 34) | ||
|---|---|---|---|---|
US (n = 16) | Mexico (n = 30) | US (n = 12) | Mexico (n = 22) | |
Age (years) | ||||
Mean (SD) | 38.4 (18.8) | 39.0 (13.5) | 37.0 (14.1) | 38.6 (11.4) |
Range | 19.0–84.0 | 22.0–67.0 | 22.0–65.0 | 23.0–55.0 |
Gender (N, %) | ||||
Female | 9 (56.3) | 22 (73.3) | 6 (50.0) | 11 (50.0) |
Ethnicity (N, %) | ||||
Not Hispanic or Latino | 15 (93.8) | 0 (0.0) | 11 (91.7) | 0 (0.0) |
Hispanic or Latino | 1 (6.3) | 30 (100.0) | 1 (8.3) | 22 (100.0) |
Race (N, %)a | ||||
American Indian or Alaska Native | 3 (18.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Asian | 2 (12.5) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
Black or African American | 2 (12.5) | 0 (0.0) | 4 (33.3) | 0 (0.0) |
White | 11 (68.8) | 1 (3.3) | 7 (58.3) | 0 (0.0) |
Mestizo | 1 (6.3) | 29 (96.7) | 0 (0.0) | 22 (100.0) |
Other | 2 (12.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Educational status adults (N, %) | ||||
Less than high school | 0 (0.0) | 4 (13.3) | 0 (0.0) | 0 (0.0) |
High school graduate or equivalent | 1 (6.3) | 8 (26.7) | 1 (8.3) | 4 (18.2) |
Some college or university, bachelor’s degree, or post graduate education | 15 (93.8) | 18 (60.0) | 11 (91.7) | 15 (68.2) |
Other | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (13.6) |
Time interval to interview (mean days, SD) | ||||
First notice symptoms to interview | 5.4 (2.3) | <7 | 12.1 (4.3) | 10.8 (9.9) |
First notice symptoms to clinic visit | 1.8 (1.2) | <7 | 2.7 (2.9) | 4.0 (4.5) |
Clinic visit to interview date | 3.6 (2.0) | <7 | 9.4 (3.7) | 6.8 (7.4) |
Medications for influenzaa(N, % Yes) | ||||
None | 1 (6.3) | 0 (0.0) | 2 (16.7) | 0 (0.0) |
Oseltamivir (Tamiflu) | 8 (50.0) | 15 (50.0) | 6 (50.0) | 9 (40.9) |
OTC symptom relief | 13 (81.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other | 0 (0.0) | 0 (0.0) | 9 (75.0) | 19 (86.4) |
Health conditions (N, %) | ||||
None | 9 (56.3) | 18 (60.0) | 4 (33.3) | 13 (59.1) |
Asthma or other lung condition | 0 (0.0) | 0 (0.0) | 3 (25.0) | 7 (31.8) |
Depression | 0 (0.0) | 0 (0.0) | 2 (16.7) | 0 (0.0) |
Diabetes | 1 (6.3) | 5 (16.7) | 1 (8.3) | 0 (0.0) |
Heart attack/angina | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
Hypertension | 1 (6.3) | 0 (0.0) | 4 (33.3) | 2 (9.1) |
Kidney disease | 0 (0.0) | 0 (0.0) | 2 (16.7) | 0 (0.0) |
Lung disease | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
Osteoporosis | 1 (6.3) | 0 (0.0) | 1 (8.3) | 0 (0.0) |
Raised cholesterol | 1 (6.3) | 0 (0.0) | 2 (16.7) | 0 (0.0) |
Stomach ulcer | 1 (6.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Tuberculosis | 1 (6.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Other health conditions | 6 (37.5) | 0 (0.0) | 4 (33.3) | 3 (13.6) |
Cardiovascular disorder | 0 (0.0) | 4 (13) | 0 (0.0) | 0 (0.0) |